novartis_outside_1

Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis

pharmafile | August 3, 2020 | News story | Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis 

Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients between the ages of six and 18 with moderate-to-severe plaque psoriasis.

The ruling was secured on the back of data from two Phase 3 studies which demonstrated the safety and efficacy of low and high dosages (75-150mg and 75-300mg) in improving skin symptoms and quality of life. According to this latest approval, the recommended dose for children weighing up to 50 kg is 75 mg, and 150 mg for children 50 kg and over.

“Psoriasis is a life-long debilitating disease that significantly impacts children’s quality of life, both physically and emotionally. There are only a few approved treatment options available for the paediatric population and so it is important to broaden the adult therapeutic options out to children when possible,” said Professor Christine Bodemer, Head of the Department of Dermatology, Necker–Enfants Malades Hospital. “This approval means Cosentyx is now available in Europe for children and adolescents, and will provide an additional option to quickly gain relief from their symptom burden and to significantly improve their quality of life.”

Novartis said it was already at work in order to make the therapy available to eligible patients “as quickly as possible”.

Matt Fellows

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …

Latest content